Click to Download
PRESS RELEASE
26 November 2025
Press Release
Media Contacts:
IB Communications
eXmoor Pharma and Royal Free London launch strategic collaboration to strengthen UK cell and gene therapy manufacturing pathway
Bristol and London, UK, 26 November 2025 - eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Royal Free London NHS Foundation Trust, through its Cell and Vector Innovation Centre (CVIC), have entered a strategic collaboration to build a seamless, scalable pathway for cell and gene therapy development and manufacturing in the UK.
The collaboration brings together CVIC's early-phase clinical manufacturing expertise with eXmoor’s later-phase clinical manufacturing capabilities and its planned progression toward a commercial manufacturing license. Together, the organisations aim to create a joined-up translational pathway that reduces complexity, accelerates timelines, and strengthens the UK’s position as a global leader in advanced therapeutics.
Linking early innovation with commercial-scale delivery
By aligning technical transfer processes, quality systems, and regulatory expertise, the collaboration will enable more efficient transitions between early and later stages of manufacturing. This will help academic, clinical, and commercial innovators navigate the journey from proof of concept through to first-in-human trials and ultimately commercial launch.
Joint areas of focus include:
Development of harmonised technology transfer protocols, quality frameworks, and digital documentation
Shared expertise in Qualified Person (QP) responsibilities, regulatory strategy, and quality management
Collaborative process development, technical consultation, and regulatory problem-solving
Staff training programmes and knowledge exchange across both organisations
By establishing a trusted model for academic-industry collaboration, the partnership aims to provide greater clarity to early-stage innovators on long-term commercial feasibility, while creating a platform to demonstrate robust UK-based manufacturing routes to both domestic and international stakeholders.
Angela Osborne, Founder & Executive Chair of eXmoor Pharma, commented:
“This collaboration is a powerful example of how the UK’s strength in early research can be matched with long-term manufacturing foresight. CVIC is doing vital work in early-phase GMP, and by connecting that with eXmoor’s development and commercialisation expertise, we can create a clearer, more supportive route to bring promising therapies to patients. It’s about strengthening the UK ecosystem so that innovation stays here and thrives here.”
Owen Bain, Director of CVIC, Royal Free London NHS Foundation Trust, said:
“For the UK’s cell and gene therapy sector to truly thrive, key learnings must flow freely across institutional and commercial boundaries. This collaboration is designed to do exactly that - connecting NHS early-phase experience with eXmoor’s development and commercial manufacturing expertise. By sharing practical know-how, aligning standards, and building mutual understanding, we can catalyse the manufacturing pathway for the next wave of innovators and create a stronger, more resilient UK ecosystem for advanced therapies.”
About eXmoor Pharma
eXmoor Pharma is the only integrated cell and gene therapy CDMO with over 20 years of consultancy expertise embedded at every stage of development. From early-phase strategy and process development to GMP manufacturing and commercialisation, eXmoor supports clients with deep technical knowledge, regulatory insight and flexible manufacturing solutions. With a purpose-built facility in Bristol, UK, and over 170 clients globally, eXmoor is a trusted partner for cell and gene therapy innovators looking to scale their therapies safely and efficiently.
About CVIC and Royal Free London NHS Foundation Trust
The Cell and Vector Innovation Centre (CVIC) is a state-of-the-art GMP facility operated by Royal Free London NHS Foundation Trust. Located on the Royal Free Hospital campus, CVIC supports early-phase clinical trials in cell and gene therapy by offering GMP manufacturing capability, regulatory expertise, and translational support to researchers and therapy developers. CVIC plays a key role in advancing the NHS’s leadership in advanced therapies, helping to move cutting-edge science from the lab to the clinic.